The potential of plants as a system for the development and production of human biologics.

F1000Research

Volumn 5, Issue , 2016, Pages

  Chen, Qiang ^a   Davis, Keith R ^b  

^a ARIZONA STATE UNIVERSITY   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; COLICIN; INFLUENZA VACCINE; TALIGLUCERASE ALFA; ZMAPP;

CELL ENCAPSULATION; DRUG SYNTHESIS; EBOLA HEMORRHAGIC FEVER; ESCHERICHIA COLI INFECTION; FOOD AND DRUG ADMINISTRATION; GAUCHER DISEASE; GOOD MANUFACTURING PRACTICE; HUMAN; INFLUENZA; INFLUENZA VIRUS; NICOTIANA BENTHAMIANA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLANT; PLANT CELL; PROTEIN ENGINEERING; PROTEIN SYNTHESIS; REVIEW; VIRUS LIKE AGENT;

EID: 85010840003     PISSN: None     EISSN: 20461402     Source Type: Journal    
DOI: 10.12688/F1000RESEARCH.8010.1     Document Type: Review

References (32)

1. Lyon GM, Mehta AK, Varkey JB, et al.: Clinical care of two patients with Ebola virus disease in the United States. N Engl J Med. 2014; 371(25): 2402-9.
2. Arntzen C: Plant-made pharmaceuticals: from 'Edible Vaccines' to Ebola therapeutics. Plant Biotechnol J. 2015; 13(8): 1013-6.
3. Tusé D, Tu T, McDonald KA: Manufacturing economics of plant-made biologics: case studies in therapeutic and industrial enzymes. Biomed Res Int. 2014; 2014: 256135.
4. Chen Q, He J, Phoolcharoen W, et al.: Geminiviral vectors based on bean yellow dwarf virus for production of vaccine antigens and monoclonal antibodies in plants. Hum Vaccin. 2011; 7(3): 331-8.
5. Klimyuk V, Pogue G, Herz S, et al.: Production of recombinant antigens and antibodies in Nicotiana benthamiana using 'magnifection' technology: GMPcompliant facilities for small-and large-scale manufacturing. Curr Top Microbiol Immunol. 2014; 375: 127-54.
6. Peyret H, Lomonossoff GP: When plant virology met Agrobacterium: the rise of the deconstructed clones. Plant Biotechnol J. 2015; 13(8): 1121-35.
7. Bendandi M, Marillonnet S, Kandzia R, et al.: Rapid, high-yield production in plants of individualized idiotype vaccines for non-Hodgkin's lymphoma. Ann Oncol. 2010; 21(12): 2420-7.
8. Werner S, Breus O, Symonenko Y, et al.: High-level recombinant protein expression in transgenic plants by using a double-inducible viral vector. Proc Natl Acad Sci U S A. 2011; 108(34): 14061-6.
9. Dugdale B, Mortimer CL, Kato M, et al.: In plant activation: an inducible, hyperexpression platform for recombinant protein production in plants. Plant Cell. 2013; 25(7): 2429-43.
10. Strasser R, Altmann F, Steinkellner H: Controlled glycosylation of plantproduced recombinant proteins. Curr Opin Biotechnol. 2014; 30: 95-100.
11. Lai H, He J, Hurtado J, et al.: Structural and functional characterization of an anti-West Nile virus monoclonal antibody and its single-chain variant produced in glycoengineered plants. Plant Biotechnol J. 2014; 12(8): 1098-107.
12. Olinger GG Jr, Pettitt J, Kim D, et al.: Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci U S A. 2012; 109(44): 18030-5.
13. Kwon KC, Daniell H: Low-cost oral delivery of protein drugs bioencapsulated in plant cells. Plant Biotechnol J. 2015; 13(8): 1017-22.
14. Su J, Sherman A, Doerfler PA, et al.: Oral delivery of Acid Alpha Glucosidase epitopes expressed in plant chloroplasts suppresses antibody formation in treatment of Pompe mice. Plant Biotechnol J. 2015; 13(8): 1023-32.
15. Su J, Zhu L, Sherman A, et al.: Low cost industrial production of coagulation factor IX bioencapsulated in lettuce cells for oral tolerance induction in hemophilia B. Biomaterials. 2015; 70: 84-93.
16. Lakshmi PS, Verma D, Yang X, et al.: Low cost tuberculosis vaccine antigens in capsules: expression in chloroplasts, bio-encapsulation, stability and functional evaluation in vitro. PLoS One. 2013; 8(1): e54708.
17. Huang Z, Phoolcharoen W, Lai H, et al.: High-level rapid production of full-size monoclonal antibodies in plants by a single-vector DNA replicon system. Biotechnol Bioeng. 2010; 106(1): 9-17.
18. Castilho A, Bohorova N, Grass J, et al.: Rapid high yield production of different glycoforms of Ebola virus monoclonal antibody. PLoS One. 2011; 6(10): e26040.
19. Zeitlin L, Pettitt J, Scully C, et al.: Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant. Proc Natl Acad Sci U S A. 2011; 108(51): 20690-4.
20. Buyel JF, Twyman RM, Fischer R: Extraction and downstream processing of plant-derived recombinant proteins. Biotechnol Adv. 2015; 33(6 Pt 1): 902-13.
21. Fulton A, Lai H, Chen Q, et al.: Purification of monoclonal antibody against Ebola GP1 protein expressed in Nicotiana benthamiana. J Chromatogr A. 2015; 1389: 128-32.
22. Qiu X, Wong G, Audet J, et al.: Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature. 2014; 514(7520): 47-53.
23. D'Aoust MA, Couture MM, Charland N, et al.: The production of hemagglutininbased virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza. Plant Biotechnol J. 2010; 8(5): 607-19.
24. Chen BJ, Leser GP, Morita E, et al.: Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles. J Virol. 2007; 81(13): 7111-23.
25. Zimran A, Brill-Almon E, Chertkoff R, et al.: Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood. 2011; 118(22): 5767-73.
26. Fox JL: First plant-made biologic approved. Nat Biotechnol. 2012; 30: 472.
27. Shaaltiel Y, Gingis-Velitski S, Tzaban S, et al.: Plant-based oral delivery of β-glucocerebrosidase as an enzyme replacement therapy for Gaucher's disease. Plant Biotechnol J. 2015; 13(8): 1033-40.
28. Schulz S, Stephan A, Hahn S, et al.: Broad and efficient control of major foodborne pathogenic strains of Escherichia coli by mixtures of plantproduced colicins. Proc Natl Acad Sci U S A. 2015; 112(40): E5454-60.
29. Buyel JF, Fischer R: Downstream processing of biopharmaceutical proteins produced in plants: the pros and cons of flocculants. Bioengineered. 2014; 5(2): 138-42.
30. Ma JK, Drossard J, Lewis D, et al.: Regulatory approval and a first-in-human phase I clinical trial of a monoclonal antibody produced in transgenic tobacco plants. Plant Biotechnol J. 2015; 13(8): 1106-20.
31. Paul MJ, Thangaraj H, Ma JK: Commercialization of new biotechnology: a systematic review of 16 commercial case studies in a novel manufacturing sector. Plant Biotechnol J. 2015; 13(8): 1209-20.
32. Holtz BR, Berquist BR, Bennett LD, et al.: Commercial-scale biotherapeutics manufacturing facility for plant-made pharmaceuticals. Plant Biotechnol J. 2015; 13(8): 1180-90.